Skip to main content

Table 2 Issues covered when discussing PSA screening (n = 88a, n (%))

From: General practitioners’ approaches to prostate-specific antigen testing in the north-east of the Netherlands

Issue Never Rarely Sometimes Often Always
Impact on general mortality 15 (19.7) 14 (18.4) 12 (15.8) 27 (35.5) 8 (10.5)
Impact on disease-specific mortality 9 (11.8) 9 (11.8) 14 (18.4) 32 (42.1) 12 (15.8)
Impact on chances of metastasis 26 (34.2) 21 (27.6) 13 (17.1) 12 (15.8) 4 (5.3)
Overdiagnosis 1 (1.3) 3 (3.8) 10 (12.8) 34 (43.6) 30 (38.5)
False-positive test results 2 (2.6) 4 (5.1) 6 (7.7) 33 (42.3) 33 (42.3)
Anxiety when awaiting test results 15 (19.5) 17 (22.1) 15 (19.5) 17 (22.1) 13 (16.9)
Possibility of further diagnostic tests 2 (2.6) 0 (0.0) 14 (17.9) 36 (46.2) 26 (33.3)
Possible consequences of medical policy b 2 (2.6) 3 (3.9) 11 (14.3) 41 (53.2) 20 (26.0)
Referral to Thuisarts.nl (webpage) c 4 (5.1) 8 (10.3) 19 (24.4) 34 (43.6) 13 (16.7)
Provide handout 24 (30.8) 23 (29.5) 18 (23.1) 8 (10.3) 5 (6.4)
  1. PSA Prostate-specific antigen, a = numbers (%) of participants. Numbers may not add up to total, due to missing values, b = e.g. side effects of further diagnostics/treatment in case of positive test result, c = in the Dutch GP guideline referral to this website is recommended to help the patient to decide on PSA screening